Redcare Pharmacy Shares: A Cautious Rebound Amid Persistent Challenges

Redcare Pharmacy shares surge over 20% on short covering, but deep structural challenges and lowered financial targets cast doubt on the rally's sustainability.

A surge of over 20 percent in just two trading sessions typically signals a powerful turnaround. For Redcare Pharmacy, however, the recent share price advance comes with significant caveats. While technical factors have fueled the rally, the company's underlying structural issues remain firmly in place, casting doubt on the sustainability of the gains.

Rallying from a Multi-Year Low

To understand the current movement, one must consider the stark context. Since early May 2025, Redcare's stock had plummeted approximately 76 percent, hitting a five-year low just above €30.82 last week. Even after this week's powerful bounce, the shares remain down about 42 percent since the start of the year. This performance places Redcare second-to-last on the MDAX index for 2026, with only used-car platform Auto1 Group faring worse.

Short Covering Provides a Technical Boost

A primary driver behind the two-day advance has been short covering. The stock had attracted considerable interest from short-sellers, many of whom have now moved to close their positions. This process involves buying back shares to unwind their bearish bets, a mechanism that can dramatically amplify upward price moves in a heavily shorted equity like Redcare.

The rally found additional, albeit modest, support from external analysis. Bankhaus Metzler highlighted a proposed reform package for Germany’s statutory health insurance system, which contains 66 suggestions. One point of particular relevance for mail-order pharmacies is a potential increase in co-payments for prescription medicines for publicly insured patients. Notably, competitor DocMorris also saw gains in Zurich, though its rise was a more modest 1.6 percent.

Unchanged Fundamental Headwinds

Beneath the short-term price action, Redcare's core challenges persist unchanged. The competitive landscape was fundamentally altered by the December 2025 market entry of dm-med and similar announced plans from Rossmann, particularly in the over-the-counter (OTC) segment. In its annual report published on March 4, Redcare significantly downgraded its medium-term targets: the OTC growth goal was slashed from 16 percent to a range of 8-10 percent, while the target EBITDA margin was reduced from 8 percent to 5 percent.

The 2025 financial results presented a mixed picture. While German prescription (Rx) revenue nearly doubled to €503 million and group sales rose to €2.94 billion, the gross margin contracted from 22.3 percent to 21.3 percent. This decline is a direct consequence of the growing proportion of lower-margin prescription medicines in the sales mix.

The Prescription Business as a Defensive Pillar

Amid the OTC pressures, Redcare's regulated prescription drug operations provide a more stable foundation. Rossmann has confirmed that its planned online pharmacy will not offer prescription medications. Leveraging its CardLink license, valid until January 2027, and the integration of the GesundheitsID (Health ID), Redcare is targeting Rx revenue exceeding €670 million for 2026.

All eyes are now on the upcoming quarterly report due on May 6, 2026. This will be the first under the company's new leadership and is widely seen as the initial concrete indicator of whether the recently initiated strategic shift is gaining traction.